Nama's AI scorecard currently rates Revvity Hold (5.6 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is RVTY's P/E ratio?

Revvity trades at a trailing price-to-earnings ratio of 28.0.

When does RVTY report earnings?

Revvity's next scheduled report is on Feb 1, 2027. Analysts expect EPS of $1.62.

What is the RVTY price target?

The median analyst price target from 15 analysts is $164.00, with a range of $110.00 – $185.00.

Is RVTY Shariah compliant?

Nama's AAOIFI-style screen reads Revvity as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Does RVTY pay a dividend?

Yes — Revvity's dividend yield is 0.2%.

Nama Insights

Revvity (RVTY)

Healthcare · Diagnostics Research · NYSE

S&P 500

Revvity (RVTY) is a Healthcare company in the Diagnostics Research industry. It has a market capitalization of $17.31B, a trailing price-to-earnings ratio of 28.0 and a free-cash-flow yield of 2.8%. Over the most recent reported fiscal year, revenue grew 3.7% and free cash flow per share fell 0.9%. Nama's AI scorecard rates it Hold, 5.6 out of 10. On 12-month momentum it ranks in the leading band of its market.

AI scorecard

Hold · 5.6/10

The sections balance. As of Nov 7, 2026.

Momentum

Leading · +71.6% over 12 months ex. last

Top 20% of its market on the past year's steady rise.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-23.6%

How far the last close sits under the highest price of the past five years.

Market cap	$17.31B
Trailing P/E	28.0
Price / book	2.4
Price / sales	6.0
FCF yield	2.8%
Dividend yield	0.2%
Gross margin	55.0%
Operating margin	12.3%
Net margin	8.2%
Revenue growth (YoY)	+3.7%
Revenue growth (3-yr annual)	-4.8%
EPS growth (YoY)	+3.5%
FCF/share growth (YoY)	-0.9%
Beta	1.1
Exchange	NYSE
Sector	Healthcare
Industry	Diagnostics Research

RVTY earnings

Next report: Feb 1, 2027 (Q4 2026, EPS estimate $1.62). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 3, 2026	$1.37	$1.30	+5.4%	—
Q2 2026	Aug 4, 2026	$1.41	$1.22	+15.6%	$729.69M
Q1 2026	May 5, 2026	$1.06	$1.01	+5.0%	$711.12M
Q4 2025	Feb 2, 2026	$1.70	$1.58	+7.6%	$772.06M

RVTY analyst price target

Median target $164.00 from 15 analysts, ranging $110.00 – $185.00.

Diagnostics Research peers

Ticker	Company	Market cap	P/E
TMO	Thermo Fisher Scientific	$257.42B	28.1
DHR	Danaher	$161.86B	27.6
IDXX	IDEXX Laboratories	$53.26B	45.6
A	Agilent Technologies	$49.28B	28.8
WAT	Waters	$44.93B	31.8
IQV	IQVIA	$44.80B	21.2
NTRA	Natera	$44.78B	—
MTD	Mettler-Toledo International	$34.51B	37.2

Explore live RVTY data on Nama Insights →

Recent Congressional trades

Revvity trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Gilbert Cisneros	House	Sell	$1,001 - $15,000	Oct 12, 2026
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Sep 12, 2025
Lisa McClain	House	Sell	$1,001 - $15,000	Aug 13, 2025
Lisa McClain	House	Buy	$1,001 - $15,000	Aug 13, 2025
April McClain Delaney	House	Sell	$15,001 - $50,000	Mar 20, 2025

RVTY FAQ

Is RVTY a buy?: Nama's AI scorecard currently rates Revvity Hold (5.6 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is RVTY's P/E ratio?: Revvity trades at a trailing price-to-earnings ratio of 28.0.
When does RVTY report earnings?: Revvity's next scheduled report is on Feb 1, 2027. Analysts expect EPS of $1.62.
What is the RVTY price target?: The median analyst price target from 15 analysts is $164.00, with a range of $110.00 – $185.00.
Is RVTY Shariah compliant?: Nama's AAOIFI-style screen reads Revvity as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.
Does RVTY pay a dividend?: Yes — Revvity's dividend yield is 0.2%.